PEG-Intron peginterferon alfa-2b: Phase III data; under FDA and EMEA review

ENZN partner Schering-Plough Corp. (SGP, Madison, N.J.) reported results of a 1,219-patient Phase III trial showing

Read the full 160 word article

How to gain access

Continue reading with a
two-week free trial.